The Lilly Technology Center manufacturers insulin and the expansion will increase the company’s capacity to make other diabetes medicines, officials wrote.
The investment is expected to improve the company’s syringe-filling, device assembly and packaging operations, Eli Lilly said.
Eli Lilly has faced criticism in the past for the high price of its insulin. Earlier this year, the drugmaker’s generic version of insulin was approved in March 2019, though in August 2019, most prescriptions were still for the brand-name Humalog insulin.
Read the full news release here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020
